Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20
BW Businessworld

Cipla Receives Final Approval For Generic Version Of Shire’s Firazyr®

Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

Photo Credit :

1594710414_obS0J2_image001.jpg

Cipla Ltd received the final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration (US FDA).

Cipla’s Icatibant Injectable Pre-Filled Syringe 30mg/3mL is AP-rated generic version of Shire’s Firazyr®. Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

Firazyr® and its generic equivalents had US sales of approximately $270M for the 12-month period ending May 2020, as per IQVIA (IMS Health).




Tags assigned to this article:
cipla pharmaceutical us fda anda